Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial by �씠�긽湲�
ORiginal Article
Background/Aims: To evaluate the efficacy and safety of 
a controlled release, once-daily formulation of mosapride 
(UI05MSP015CT) in patients with functional dyspepsia (FD). 
Methods: Patients with FD were randomly assigned (1:1) 
to receive either UI05MSP015CT (15 mg once a day, study 
group) or mosapride (5 mg three times a day, control group) 
and corresponding placebo for 4 weeks. The primary end-
point was a change in the gastrointestinal symptom score 
(GIS) evaluated at enrollment and after 4 weeks. Secondary 
endpoints were changes in the Nepean Dyspepsia Index-Ko-
rean version (NDI-K), rate of satisfactory symptom relief, and 
rate of adverse events. Results: A total of 138 patients were 
enrolled (female, 73.9%; mean age, 44.0±15.4 years). After 
excluding patients who violated the study protocol, 59 and 
58 patients from the study and control groups, respectively, 
were included in the per-protocol analysis. No difference 
was observed in drug compliance between the control and 
study groups (97.07%±4.52% vs 96.85%±6.05%, p=0.870). 
Changes in GIS scores were –9.69±6.44 and –10.01±5.92 
in the study and control groups. The mean difference in 
GIS change between groups was 0.33 (95% confidence 
interval, –1.75 to 2.41), demonstrating non-inferiority of UI-
05MSP015CT (p=0.755). The rate of satisfactory symptom 
relief was not different between the study and control groups 
(39.0% vs 56.9%, p=0.053). No differences in change in 
NDI-K score (14.3 vs 16.9, p=0.263) or rates of adverse 
events (12.9% vs. 4.4%, p=0.062) were observed between 
the study and control groups. Conclusions: Once-daily mo-
sapride is not inferior to conventional mosapride in efficacy 
and is safe in patients with FD. (Gut Liver 2018;12:516-
522)
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INTRODUCTION
Mosapride is a selective 5-hydroxytryptamine 4 (5-HT4) re-
ceptor agonist, which facilitates motility of smooth muscle in 
the gastrointestinal tract and increases gastric emptying by 
promoting the release of acetylcholine at nerve terminals in the 
mesenteric plexus.1,2 As mosapride has low affinity for 5-HT1, 
5-HT2, α1, α2, and D2 receptors in the gastrointestinal tract, it 
does not cause side effects such as arrhythmia, extrapyramidal 
symptoms, and hyperprolactinemia that are common for most 
prokinetics.3 Efficacy of mosapride in the treatment of func-
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tional dyspepsia was demonstrated in many clinical studies.4-6 
In addition to relieving symptoms, mosapride was also reported 
to improve quality of life of patients with functional dyspepsia.7
UI05MSP015CT (Gastiin CR®, Korea United Pharm. Inc., 
Seoul, Korea) is a controlled release mosapride tablet, newly de-
veloped to increase patient convenience and compliance using 
sustained-release double-layer tablet formulation. Mosapride 
UI05MSP015CT formulation consists of two layers, providing 
immediate and sustained drug release. Immediate-release layer 
(mosapride citrate 5 mg) is instantly released and dissolves rap-
idly within 30 minutes of administration, whereas the sustained-
release layer (mosapride citrate 10 mg) is a hydrophilic matrix-
type tablet slowly dissolving over 24 hours. Pharmacokinetic 
profile of the formulation allows once-daily administration of 
UI05MSP015CT. In a phase I clinical trial in healthy male vol-
unteers aged 20 to 55 years, UI05MSP015CT showed a pharma-
cokinetic profile similar to that of conventional mosapride.8
In this study, we performed a phase III clinical trial to dem-
onstrate non-inferiority of UI05MSP015CT to mosapride in pa-
tients with functional dyspepsia.
MATERIALS AND METHODS
1. Patients
The inclusion criteria were as follows: (1) age >19 years; (2) 
diagnosis of functional dyspepsia meeting Rome III criteria (pre-
senting at least one symptom among bothersome postprandial 
fullness, early satiation, epigastric pain or epigastric burning 
at least 6 months before the study, with >3 months duration);9 
(3) at least three moderate or severe symptoms included in the 
gastrointestinal symptom score (GIS),10,11 with severity of 10 
GIS items (nausea, vomiting, bloating, abdominal cramps, early 
satiety, acid eructation/heartburn, sickness, loss of appetite, 
retrosternal discomfort, and epigastric or upper abdominal pain) 
experienced in the last 2 weeks was evaluated by summing up 
scores from a 5-point Likert scale (0–4, no symptom, minor, 
moderate, severe, and extremely severe symptom, respectively); 
(4) no structural lesions of upper gastrointestinal tract detected 
endoscopically 12 weeks prior to enrollment. Although proki-
netics is preferentially recommended for the treatment of func-
tional dyspepsia of postprandial distress syndrome subtype,12 
there is still a lack of qualified studies evaluating treatment 
response according to each subtype of functional dyspepsia us-
ing Rome criteria III.13 In addition, because mosapride is effec-
tive in epigastric pain syndrome subtype as well as postprandial 
distress syndrome subtype,4-6 we included patients with both 
subtypes of functional dyspepsia in this study. Similar to the 
previous study that evaluated prevalence and characteristics of 
functional dyspepsia using Rome III questionnaire in Korea,14 
patients who had epigastric pain or burning but who did not 
completely satisfy epigastric pain syndrome criteria were classi-
fied as nonspecified type of functional dyspepsia. An additional 
criterion (nausea, vomiting, and acid eructation/heartburn pres-
ent among GIS items) was added after Korea Food and Drug 
Administration recommended the evaluation of efficacy of 
UI05MSP015CT for approved indication of mosapride in Korea 
(improvement of these symptoms stemming from functional 
dyspepsia).
Exclusion criteria were as follows: (1) history of dyspepsia 
unrelated to functional dyspepsia or diseases that may affect 
evaluation of efficacy in the previous 6 months; (2) history of 
gastrointestinal surgery; (3) history of malignancy in the previ-
ous 5 years; (4) psychiatric disorders including major depres-
sive disorder and anxiety; (5) liver cirrhosis or abnormal liver 
laboratory findings (>3 times upper normal limit of aspartate or 
alanine aminotransferase levels); (6) advanced chronic kidney 
disease (creatinine clearance <30 mL/min); (7) uncontrolled hy-
pertension (systolic/diastolic blood pressure ≥160/100 mmHg); 
(8) uncontrolled diabetes (HbA1c >8%); (9) pregnancy and 
lactation; (10) recent history of taking medication affecting the 
gastrointestinal system: prokinetics, erythromycin, acid release 
inhibitors (histamine 2 receptor antagonists, proton pump inhib-
itors, or potassium-competitive acid blockers), gastric mucosa 
protectors, fundal relaxants (sumatriptan, buspirone), choliner-
gics, anticholinergics, antispasmodics, antidepressants (tricyclic 
antidepressants and selective serotonin reuptake inhibitors), as-
pirin over 100 mg/day, systemic nonsteroidal anti-inflammatory 
drugs, and systemic glucocorticosteroids. Patients treated with 
any of the listed drugs who wished to participate in this study 
were eligible for enrollment after a wash-out period of 2 weeks.
2. Study design
This study was designed as a multicenter, randomized, active-
controlled, double-blind, non-inferiority, phase III clinical trial 
evaluating efficacy and safety of UI05MSP015CT in functional 
dyspepsia. After a 2-week wash-out period, patients with func-
tional dyspepsia were randomly assigned (1:1) to receive either 
UI05MSP015CT (15 mg once daily before breakfast, study 
group) or mosapride (Gasmotin®; Daewoong Pharmaceutical, 
Seoul, Korea) (5 mg three times a day before each meal, control 
group) and corresponding placebo three times a day or once a 
day for 4 weeks. This trial was registered at ClinicalTrials.Gov 
(NCT03225248). In addition, this study was approved by the In-
stitutional Review Board of Seoul National University Bundang 
Hospital (IRB number: B-1407/260-005) and all other institu-
tions. All patients provided informed consent.
All patients underwent a urea breath test before enrollment to 
ascertain Helicobacter pylori infection status. GIS was evaluated 
at enrollment, and after 2 and 4 weeks of treatment. Nepean 
Dyspepsia Index-Korean version (NDI-K) questionnaire was ad-
ministered at enrollment and after 4 weeks of treatment. Drug 
compliance was determined by monitoring the unused amount 
of the clinical trial drug returned by the patients who visited the 
clinic of each hospital after 2 and 4 weeks of treatment.
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Primary endpoint was the change of total GIS score, evalu-
ated at enrollment and after 4 weeks. Secondary endpoints were 
rate of satisfactory symptom relief, change in quality of life 
evaluated using NDI-K, and rate of adverse events. Symptom 
relief was assessed as follows. Patients were asked “How much 
has the dyspepsia symptom improved in the last 2 weeks com-
pared to dyspepsia before treatment start?” and responded by 
selecting: “loss of symptom,” “apparent improvement,” “moder-
ate improvement,” “no change,” and “deterioration.” Rate of 
satisfactory symptom relief was defined as the proportion of 
enrolled patients who answered as “loss of symptom” or “appar-
ent improvement.” NDI-K consists of 25 questions on five qual-
ity of life areas: stress/sleep, disturbance of daily life, eating/
drinking, knowledge and control, and work/study. Questions are 
scored 1–5 points, with higher score indicating better quality 
of life. Importance of the five quality of life areas was weighed 
by the patients (scale of 1–5) and the associated question scores 
were multiplied by the weighing factors before summation to 
obtain area scores. Area scores were converted using the follow-
ing formula: ([area score – minimum area score]/score range of 
each area)×100. Total NDI-K score was calculated by summing 
converted area scores.
Adverse events that occurred during the clinical trial were 
classified as treatment-emergent adverse events, adverse drug 
reactions, and serious adverse events. A treatment-emergent 
adverse event was defined as any event not present prior to the 
initiation of the treatments or any event already present that 
worsens in either intensity or frequency following exposure to 
the treatments. An adverse drug reaction was defined as any 
adverse event for which there is a reasonable possibility that the 
drug caused the adverse event; “reasonable possibility” means 
there is evidence to suggest a causal relationship between the 
drug and adverse event. An adverse event was considered “se-
rious” if it results in any of the following outcomes: death, a 
life-threatening adverse event, inpatient hospitalization or pro-
longation of existing hospitalization, a persistent or significant 
incapacity or substantial disruption of the ability to conduct 
normal life functions, or a congenital anomaly/birth defect.
Enrolled patients receiving at least one clinical trial drug were 
included in intention-to-treat (ITT) analysis, whereas patients 
who completed the clinical trial without major protocol viola-
tions were included in per-protocol (PP) analysis. Major proto-
col violations included dropout, breach of inclusion/exclusion 
criteria, taking a prohibited drug, study drug compliance <80%, 
deviation from scheduled clinic visit date, and mistakes in treat-
ment dispensation.
3. Statistical analysis
SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA) 
was used for the statistical analysis. Continuous variables were 
analyzed using Student t-test. The chi-square test or Fisher ex-
act test were used to analyze categorical variables. Two-sided 
95% confidence interval (CI) was calculated for the difference 
in the change of GIS score after 4 weeks between the groups. 
In the studies that evaluated the efficacy of prokinetic agents 
similar to mosapride, the change of GIS score after 4 weeks in 
the study group and control group was –6.6 to –12.1 and –1.5 
to –2.1, respectively.10,11,15 We assumed that the change of GIS 
score in our study would be weighted-mean value of the results 
of the afore-mentioned studies. Therefore, we reasoned that 
3.83, which is the 50% of weighted-mean difference of study 
and control group (–9.45 – –1.80 = –7.65) would be the ac-
ceptable upper limit of non-inferiority. Finally, taking a more 
conservative stance, non-inferiority was declared if the upper 
limit of the CI was ≤3. For sample size calculation, we set α er-
ror as 0.025 one-sided significance level and gave 80% power; 
58 Patients 59 Patients
ITT analysis
PP analysis
138 Patients with FD
Random allocation by 1:1
68 Control group 70 Study group
3 Dropout
3 Breach of inclusion/exclusion
criteria
2 Taking prohibited drug
3 Deviation from medication
compliance
4 Deviation from visit date
1 IP release error
2 Dropout
3 Breach of inclusion/exclusion
criteria
3 Deviation from medication
compliance
3 Deviation from visit date
1 IP release error
Fig. 1. Flow schematic of the study: 
intention-to-treat (ITT) and per-
protocol (PP) analyses.
FD, functional dyspepsia; IP, inves-
tigational product. Some patients 
were excluded from the study for 
several reasons.
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true difference was assumed as zero. From these backgrounds, 
52 subjects were required in each group (1:1 allocation). We 
estimated dropout rate as 30% and finally we planned to enroll 
75 subjects in each group (total 150 subjects). p-values <0.05 
were consider statistically significant. Statistical methods of this 
study were reviewed by researcher (Hak-youn Kim) from C&R 
Research, Inc.
RESULTS
Fig. 1 shows the flow schematic of the study (ITT and PP 
analyses). A total of 138 patients with functional dyspepsia 
(study group, 70; control group, 68) were enrolled between 
November 2014 and August 2015 in 19 university tertiary care 
hospitals in South Korea (ITT analysis set: female 73.9%, mean 
age 44.0±15.4 years). Because an interim analysis indicated suf-
ficient statistical power for PP analysis, recruitment was stopped 
before randomization of 150 patients. After excluding patients 
who violated study protocol (see Materials and Methods), 59 and 
58 patients from study and control groups, respectively, were 
included in PP analysis. Table 1 shows the baseline characteris-
tics of both groups (ITT analysis). The only difference between 
control and study groups was body mass index (22.03±3.51 
kg/m2 vs 23.41±3.73 kg/m2, p=0.007). The proportion of post-
prandial distress syndrome subtype was higher in control 
group than in study group, there was no statistical significance 
(48.5% vs 41.4%, p=0.207). No difference was observed in drug 
compliance between control and study groups in PP analysis 
(97.07%±4.52% vs 96.85%±6.05%, p=0.870).
Total GIS score decreased gradually in both groups during 
the study period (Fig. 2A). In PP analysis, mean change of GIS 
total score against baseline after 4 weeks was –10.03±5.53 
and –9.80±6.00 in control and study groups, respectively (Fig. 
2B). Difference in the change of GIS score between study and 
control groups was 0.24 (95% CI, –1.88 to 2.35). As the upper 
limit of the CI was <3, study drug was not inferior to control 
drug (p=0.824). No difference in the change of GIS score was 
observed between the groups for any of the symptoms after 4 
weeks (Table 2). When we performed subgroup analysis in the 
patients with postprandial distress syndrome, mean change of 
GIS total score against baseline after 4 weeks was –10.72±5.83 
and –9.28±4.88 in control and study groups, respectively. Dif-
ference in the change of GIS score between study and control 
Table 1. Baseline Patient Characteristics (Intention-to-Treat Analysis)
Characteristic
Control group 
(n=68)
Study group 
(n=70)
p-value
Age, yr 44.90±15.03 43.73±15.85 0.547
Female sex 52 (76.5) 50 (71.4) 0.444
BMI, kg/m2 22.03±3.51 23.41±3.73 0.007*
Smoking 0.708
   Never 57 (83.8) 62 (88.6)
   Past 5 (7.4) 4 (5.7)
   Current 6 (8.8) 4 (5.7)
Alcohol† 0.412
   Never 41 (60.3) 36 (51.4)
   Past 5 (7.4) 4 (5.7)
   Current 21 (30.9) 29 (41.4)
Disease duration, yr 3.90±5.23 4.06±5.83 0.569
Subtype of FD 0.207
   PDS 33 (48.5) 29 (41.4)
   EPS 1 (1.5) 0
   Non-specified 34 (50.0) 41 (58.6)
Helicobacter pylori infection 29 (42.6) 27 (38.6) 0.586
Data are presented as mean±SD or number (%).
BMI, body mass index; FD, functional dyspepsia; PDS, postprandial 
distress syndrome; EPS, epigastric pain syndrome.
*p<0.05; †There were some missing data.
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Fig. 2. Primary endpoint: GIS total score. (A) GIS total score by visit. (B) Change in GIS total score compared to baseline by visit.
GIS, gastrointestinal symptom score.
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groups was 1.44 (95% CI, –1.52 to 4.41); there was no statistical 
significance (p=0.333).
Tables 3 and 4 show the degree of symptom relief and change 
of NDI-K score, respectively, after 4 weeks in both groups in 
PP analysis. The rate of satisfactory symptom relief was differ-
ent between control and study groups in ITT analysis (55.9% vs 
37.1%, p=0.027). However, it was not different between both 
groups in PP analysis (56.9% vs 39.0%, p=0.053). No differ-
ences in change of total NDI-K score were observed in both ITT 
and PP analysis (ITT: 16.68±14.15 vs 13.79±12.23, p=0.204, PP: 
16.91±13.44 vs 14.30±11.62, p=0.263).
Table 5 shows treatment-emergent adverse events that oc-
curred during the clinical trial. No difference in the total 
number of patients with adverse events was observed between 
control and study groups (4.4% vs 12.9%, p=0.062). Gastroin-
testinal disorders were the most common adverse events in the 
study group (one case each of diarrhea, frequent bowel move-
ments, and nausea, 3/10=30.0%). Diarrhea and nausea, among 
treatment-emergent adverse events in the study group, and no 
events in the control group were classified as adverse drug reac-
tions (2.94% vs 0%, p=0.241). Among 10 adverse events in the 
study group, seven were mild and three were moderate, whereas 
all adverse events in the control group were mild. No serious 
adverse events were reported in either group.
DISCUSSION
We conducted this study applying similar disease definition, 
inclusion/exclusion criteria, and treatment duration as previous 
studies that evaluated drug efficacy in functional dyspepsia.10,11,15 
As a result, demographics of enrolled patients such as mean age 
and sex distribution were also similar to previous studies.10,11,15 
Additionally, because the baseline GIS score in both groups was 
similar to that of previous studies,10,11,15 we could confirm that 
the severity of functional dyspepsia in patients enrolled in this 
Table 2. Change in GIS Score by Symptoms after 4 Weeks (Per-
Protocol Analysis)
Symptoms
Control 
(n=58)
Study 
(n=59)
p-value
Nausea –1.19±1.02 –1.19±1.24 0.765 
Vomiting –0.48±0.94 –0.63±1.05 0.432 
Bloating –1.53±0.92 –1.44±0.91 0.542 
Abdominal cramps –0.55±0.88 –0.63±1.02 0.849 
Early satiety –1.45±0.92 –1.25±1.18 0.308 
Acid eructation/heartburn –1.50±1.01 –1.69±1.00 0.501 
Sickness –0.97±0.99 –0.80±0.92 0.332 
Loss of appetite –0.81±0.93 –0.47±1.02 0.090 
Retrosternal discomfort –0.69±0.99 –0.73±0.94 0.832 
Epigastric or upper abdominal pain –0.86±1.05 –0.97±1.08 0.502 
Data are presented as mean±SD.
GIS, gastrointestinal symptom score.
Table 3. Degree of Symptom Relief after 4 Weeks (Per-Protocol Anal-
ysis)
Control group 
(n=58)
Study group 
(n=59)
p-value
Loss of symptom 9 (15.52) 5 (8.48) -
Apparent improvement 24 (41.38) 18 (30.51) -
Moderate improvement 20 (34.48) 30 (50.85) -
No change 4 (6.90) 5 (8.48) -
Deterioration 1 (1.72) 1 (1.70) -
Satisfactory symptom relief* 33 (56.9) 23 (39.0) 0.053
Data are presented as number (%).
*Satisfactory symptom relief was defined as loss of a symptom or ap-
parent improvement.
Table 4. Change in NDI-K Score after 4 Weeks (Per-Protocol Analy-
sis)
Items
Control 
(n=58)
Study 
(n=59)
p-value
Total score 16.91±13.44 14.30±11.62  0.263
   Stress/sleep 17.61±17.15 12.92±14.80 0.116
   Disturbance of daily life 15.64±15.75 13.66±15.25 0.490
   Eating/drinking 17.15±18.80 13.94±16.46 0.328
   Knowledge and control 19.63±18.42 16.70±19.42 0.405
   Work/study 14.51±16.55 14.27±16.36 0.936
Data are presented as mean±SD.
NDI-K, Nepean Dyspepsia Index-Korean version.
Table 5. Treatment-Emergent Adverse Events (Intention-to-Treat 
Analysis)
Control group 
(n=68)
Study group 
(n=70)
p-value
Abdominal discomfort 1 (1.5) - -
Diarrhea - 1 (1.4) -
Frequent bowel movements - 1 (1.4) -
Nausea - 1 (1.4) -
Depression - 1 (1.4) -
Psychogenic pain disorder - 1 (1.4) -
Positional vertigo - 1 (1.4) -
Bronchitis - 1 (1.4) -
Pyuria 1 (1.5) - -
Dyslipidemia - 1 (1.4) -
Urinary stone - 1 (1.4) -
Cough - 1 (1.4) -
Pruritus 1 (1.5) - -
Total 3 (4.4)    9 (12.9)* 0.062
Data are presented as number (%).
*Because depression and psychogenic pain disorder occurred in the 
same subject, the total number was decreased by one.
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study was also comparable to previous results. 
In the present study, the degree of symptom improvement 
of functional dyspepsia in the study group, evaluated by the 
change of total GIS score after 4 weeks of treatment, was not 
inferior to that in control group. In addition, no difference in 
the change of specific GIS scores, rate of satisfactory symptom 
relief, and quality of life was observed between the two groups, 
indicating that efficacy of UI05MSP015CT was comparable to 
mosapride in this study. As the rate of adverse drug reactions 
was 2.94% in the study group and no serious adverse events 
were reported, safety of UI05MSP015CT was considered accept-
able.
Drug compliance is very important for successful treatment 
of many diseases, including functional dyspepsia. As the effects 
of functional dyspepsia drug treatments have been estimated to 
offer approximately 10% improvement over placebo in many 
clinical trials,16 lack of patient adherence may render the treat-
ment benefits marginal in clinical practice, leading to manifes-
tation of adverse events without definite improvement of symp-
toms. One method to increase drug compliance is reducing dose 
frequency.17 For this reason, administering drugs once a day is 
recommended in the treatment of some chronic diseases such 
as ulcerative colitis.18 Mosapride is a safe and effective drug for 
treating functional dyspepsia. However, taking mosapride three 
times a day, 30 minutes before each meal to maximize treat-
ment efficacy, makes the dosing regimen difficult for patients to 
adhere to. Whereas drug compliance is also important for short 
treatment-course (1 to 2 weeks) diseases such as H. pylori infec-
tion,19 the chronic nature of functional dyspepsia requires pa-
tients to comply with treatment over several months. Therefore, 
UI05MSP015CT, offering once a day dosing regimen, would be 
an excellent alternative to conventional mosapride in patients 
with functional dyspepsia. In this study, drug compliance was 
very good in both groups (>95%). However, if this study had 
been performed without including corresponding placebo in 
each group, compliance would be higher in the study group 
than in control group. 
It has been suggested that H. pylori may play a role in patho-
genesis of functional dyspepsia,20 with H. pylori eradication ef-
fectively improving symptoms in some patients.21 Therefore, we 
performed subgroup analysis to elucidate whether the efficacy 
of UI05MSP015CT differed based on H. pylori infection status. 
UI05MSP015CT was not inferior in efficacy to conventional 
mosapride irrespective of H. pylori infection status (data not 
shown).
This study has several limitations. First, mean body mass in-
dex of the patients in the study group was significantly higher 
than that of the patients in control group. Body mass index 
affects pharmacokinetics and pharmacodynamics of drugs, an 
effect that varies greatly depending on the type of the drug.22 
As we did not evaluate drug serum levels during this study, 
we cannot completely rule out the possibility that the differ-
ence in body mass index between groups may bias the efficacy 
comparison of control and study drugs. Second, efficacy of the 
study drug could vary between different subtypes of functional 
dyspepsia.23 Because the number of patients who completely 
satisfied criteria for epigastric pain syndrome was too small, we 
could not perform subgroup analysis in the patients with this 
subtype of functional dyspepsia. Third, although most results 
of study endpoints showed similar trends in ITT and PP analy-
sis, the rate of satisfactory symptom relief was different. It was 
lower in study group than in control group in ITT analysis. We 
could not adequately explain the cause of this finding. Finally, 
as UI05MSP015CT is formulated as a controlled release tablet 
that should be swallowed whole, not broken, ground up or 
chewed apart, this drug is not suitable for patients who require 
tube feeding.
In conclusion, administration of UI05MSP015CT to patients 
with functional dyspepsia for 4 weeks demonstrated non-inferi-
ority of this formulation to conventional mosapride in efficacy 
and a comparable safety profile. Therefore, UI05MSP015CT of-
fers a good alternative to conventional mosapride in patients 
with functional dyspepsia. 
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